Jean‐Yves Douillard

33.3k total citations · 9 hit papers
266 papers, 17.0k citations indexed

About

Jean‐Yves Douillard is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Jean‐Yves Douillard has authored 266 papers receiving a total of 17.0k indexed citations (citations by other indexed papers that have themselves been cited), including 218 papers in Oncology, 159 papers in Pulmonary and Respiratory Medicine and 38 papers in Molecular Biology. Recurrent topics in Jean‐Yves Douillard's work include Colorectal Cancer Treatments and Studies (142 papers), Lung Cancer Treatments and Mutations (108 papers) and Cancer Treatment and Pharmacology (69 papers). Jean‐Yves Douillard is often cited by papers focused on Colorectal Cancer Treatments and Studies (142 papers), Lung Cancer Treatments and Mutations (108 papers) and Cancer Treatment and Pharmacology (69 papers). Jean‐Yves Douillard collaborates with scholars based in France, United States and United Kingdom. Jean‐Yves Douillard's co-authors include Thierry Le Chevalier, Salvatore Siena, Kazuhiko Nakagawa, Martin Reck, Giuseppe Giaccone, Egbert F. Smit, Sylvie Négrier, Bernard Escudier, Shinzoh Kudoh and Frances A. Shepherd and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Jean‐Yves Douillard

265 papers receiving 16.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

2003 2.4k citations Masahiro Fukuoka, Seiji Yano et al. Journal of Clinical Oncology profile →
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

2010 1.4k citations Jean‐Yves Douillard, Salvatore Siena et al. Journal of Clinical Oncology profile →
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

2008 1.0k citations Frances A. Shepherd, Jean‐Yves Douillard et al. profile →
Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

2006 948 citations Jean‐Yves Douillard et al. Journal of Clinical Oncology profile →
Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma

1998 742 citations Sylvie Négrier, Bernard Escudier et al. profile →
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

2014 694 citations R. Kaiser, Anders Mellemgaard et al. profile →
Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.

1994 677 citations Jean‐Yves Douillard et al. Journal of Clinical Oncology profile →
Radiotherapy Alone Versus Combined Chemotherapy and Radiotherapy in Nonresectable Non-Small-Cell Lung Cancer: First Analysis of a Randomized Trial in 353 Patients

1991 623 citations Jean‐Yves Douillard et al. JNCI Journal of the National Cancer Institute profile →
Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial

2014 276 citations Jean‐Luc Raoul, Olivier Bouché et al. profile →

Peers

Countries citing papers authored by Jean‐Yves Douillard

Since Specialization

Citations

This map shows the geographic impact of Jean‐Yves Douillard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean‐Yves Douillard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean‐Yves Douillard more than expected).

Fields of papers citing papers by Jean‐Yves Douillard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean‐Yves Douillard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean‐Yves Douillard. The network helps show where Jean‐Yves Douillard may publish in the future.

Co-authorship network of co-authors of Jean‐Yves Douillard

This figure shows the co-authorship network connecting the top 25 collaborators of Jean‐Yves Douillard. A scholar is included among the top collaborators of Jean‐Yves Douillard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean‐Yves Douillard. Jean‐Yves Douillard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Threshold Change in CEA as a Predictor of Non-Progression to First-Line Systemic Therapy in Metastatic Colorectal Cancer Patients With Elevated CEA 2020 ·JNCI Journal of the National Cancer Institute ·Pat Gulhati, Jun Yin, Levi Pederson, Hans‐Joachim Schmoll, Paulo M. Hoff, Jean‐Yves Douillard, J. Randolph Hecht, Christophe Tournigand, (unknown), Benoist Chibaudel, Aimery de Gramont, Qian Shi, Michael J. Overman	24
2	Efficacy and safety of nintedanib (NIN)/docetaxel (DOC) in patients with lung adenocarcinoma: Further analyses from the LUME-Lung 1 study 2016 ·Annals of Oncology ·David F. Heigener, Maya Gottfried, Jaafar Bennouna, Igor Bondarenko, Jean‐Yves Douillard, Maciej Krzakowski, Anders Mellemgaard, Silvia Novello, Sergey Orlov, Yvonne Summers, Joachim von Pawel, (unknown), R. Kaiser, Martin Reck	2
3	PD-013 A study level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors (EGFRIs) vs bevacizumab in patients with metastatic colorectal cancer (mCRC) 2015 ·Annals of Oncology ·Volker Heinemann, Fernando Rivera, (unknown), Reija Koukakis, Jan-Henrik Terwey, Jean‐Yves Douillard	1
4	PROGNOSTIC VALUE OF EARLY OBJECTIVE TUMOR RESPONSE (EOTR) TO FIRST LINE SYSTEMIC THERAPY IN METASTATIC COLORECTAL CANCER (MCRC): INDIVIDUAL PATIENT DATA (IPD) META-ANALYSIS OF RANDOMIZED TRIALS FROM THE ARCAD DATABASE 2013 ·Asia-Pacific Journal of Clinical Oncology ·Dirkje W. Sommeijer, Qian Shi, (unknown), Katrin Marie Sjoquist, (unknown), Michel Seymour, Jim Cassidy, Richard M. Goldberg, Jean‐Yves Douillard, J. Randolph Hecht, Herbert I. Hurwitz, Christophe Tournigand, Niall C. Tebbutt, Enrique Aranda, John Souglakos, Fairooz F. Kabbinavar, Benoist Chibaudel, Aimery de Gramont, Daniel J. Sargent, John Zalcberg	2
5	Targeted therapy in metastatic colorectal cancer – An example of personalised medicine in action 2013 ·Cancer Treatment Reviews ·Volker Heinemann, Jean‐Yves Douillard, Michel Ducreux, Marc Peeters	91
6	Evaluation of KRAS, NRAS, and BRAF Mutations in Prime: Panitumumab with FOLFOX4 as First-Line Treatment in Metastatic Colorectal Cancer (MCRC) 2013 ·Annals of Oncology ·Kelly S. Oliner, Jean‐Yves Douillard, Salvatore Siena, Josep Tabernero, Ronald L. Burkes, Mario Barugel, Yves Humblet, G. Bodoky, David Cunningham, Jacek Jassem, Fernando Rivera, Ilona Kocáková, Paul Ruff, (unknown), Martin Šmakal, Richard T. Williams, Alan Rong, Jeffrey S. Wiezorek, Roger Sidhu, Scott D. Patterson	2
7	Bevacizumab Combined With Chemotherapy in the Second-Line Treatment of Metastatic Colorectal Cancer: Results from the Phase II BEVACOLOR Study 2011 ·Clinical Colorectal Cancer ·Jaafar Bennouna, Christophe Borg, Jean‐Pierre Delord, (unknown), V. Trillet-Lenoir, Roger Faroux, Éric François, Marc Ychou, François Goldwasser, Olivier Bouché, Hélène Senellart, (unknown), Jean‐Yves Douillard	26
8	An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer 2011 ·Annals of Oncology ·Anne M. Horgan, Penelope A. Bradbury, Eitan Amir, (unknown), Jean‐Yves Douillard, (unknown), Frances A. Shepherd, N. B. Leighl	21
9	Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study breakdown → 2010 ·Journal of Clinical Oncology ·Jean‐Yves Douillard, Salvatore Siena, James T. Cassidy, Josep Tabernero, Ronald L. Burkes, Mario Barugel, Yves Humblet, G. Bodoky, David Cunningham, Jacek Jassem, Fernando Rivera, Ilona Kocáková, Paul Ruff, Maria Błasińska-Morawiec, Martin Šmakal, Jean‐Luc Canon, M. Rother, Kelly S. Oliner, Michael Wolf, Jennifer Gansert	1351
10	Prime study : a randomised phase 3 study of panitumumab with Folfox4 versus Folfox4 alone as first line treatment for metastatic colorectal cancer (mCRC) 2010 ·Annals of Oncology ·Salvatore Siena, Jean‐Yves Douillard, (unknown), James T. Cassidy, Ronald L. Burkes, Mario Barugel, Yves Humblet, David Cunningham, Michael Wolf, Jennifer Gansert	1
11	Safety and Resource Utilization by Non-small Cell Lung Cancer Histology: Results from the Randomized Phase III Study of Pemetrexed Plus Cisplatin versus Gemcitabine Plus Cisplatin in Chemonaïve Patients with Advanced Non-small Cell Lung Cancer 2010 ·Journal of Thoracic Oncology ·Silvia Novello, Francisco Pimentel, Jean‐Yves Douillard, Mary O’Brien, Joachim von Pawel, John R. Eckardt, Astra M. Liepa, Lorinda Simms, Carla Visseren‐Grul, Luis Paz‐Ares	10
12	Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology 2009 ·Lung Cancer ·Cesare Gridelli, Andrea Ardizzoni, Jean‐Yves Douillard, Nasser H. Hanna, Christian Manegold, Federica Perrone, Robert Pirker, Rafael Rosell, Frances A. Shepherd, Luigi De Petris, Massimo Di Maïo, Filippo de Marinis	57
13	A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802) 2009 ·Annals of Oncology ·Marc Ychou, Jean‐Luc Raoul, Jean‐Yves Douillard, S. Gourgou-Bourgade, R. Bugat, Laurent Mineur, F. Viret, Y. Bécouarn, Olivier Bouché, E. Gamelin, Michel Ducreux, Thierry Conroy, Julia Seitz, Laurent Bedenne, A. Kramar	127
14	Cost Consequences of Adjuvant Capecitabine, Mayo Clinic and de Gramont Regimens for Stage III Colon Cancer in the French Setting 2007 ·Oncology ·Jean‐Yves Douillard, P. Tilleul, Marc Ychou, P Dufour, G. Perrocheau, J.F. Seitz, (unknown), A Lafuma, (unknown)	18
15	A meta-analysis of two randomized, double-blind, placebo-controlled, phase III studies in patients (PTS) with metastatic colorectal cancer (MCRC) receiving FOLFOX4 and PTK/ZK to determine clinical benefit on progression-free survival (PFS) in high LDH PTS 2006 ·Annals of Oncology ·Tanja Trarbach, Pierre Major, Heinz‐Josef Lenz, DJ Kerr, Kelly Pendergrass, Jean‐Yves Douillard, (unknown), Amanda Littlewood‐Evans, Laurent Dembélé, Christian Jacques, Eric Van Cutsem	2
16	Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer breakdown → 2003 ·Journal of Clinical Oncology ·Masahiro Fukuoka, Seiji Yano, Giuseppe Giaccone, Tomohide Tamura, Kazuhiko Nakagawa, Jean‐Yves Douillard, Yutaka Nishiwaki, Johan Vansteenkiste, Shinzoh Kudoh, Danny Rischin, Richard Eek, Takeshi Horai, Kazumasa Noda, Ichiro Takata, Egbert F. Smit, Steven D. Averbuch, (unknown), A. Feyereislova, (unknown), José Baselga	2392
17	Update on European adjuvant trials with irinotecan for colorectal cancer. 2002 ·PubMed ·Jean‐Yves Douillard, (unknown), Jaafar Bennouna	3
18	Prognostic factors of survival and rapid progression in782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d’Immunothérapie 2002 ·Annals of Oncology ·Sylvie Négrier, Bernard Escudier, F. Gómez, Jean‐Yves Douillard, Alain Ravaud, Christine Chevreau, M Buclon, David Pérol, Christine Lasset	273
19	A phase II trial of radiochemotherapy with daily carboplatin, after induction chemotherapy (carboplatin and etoposide), in locally advanced nonsmall-cell lung cancer: Final analysis 1997 ·International Journal of Radiation OncologyBiologyPhysics ·É. Bardet, Alain Rivière, Anne Charloux, Dominique Spaëth, A Ducoloné, A. Le Groumellec, B. Pellae-Cosset, M. Henry‐Amar, Jean‐Yves Douillard	8
20	An interleukin 2/sodium butyrate combination as immunotherapy for rat colon cancer peritoneal carcinomatosis 1994 ·Gastroenterology ·Pascale Perrin, E. Cassagnau, C Burg, (unknown), Fabienne Vavasseur, Jean Harb, Jacques Le Pendu, Jean‐Yves Douillard, Jean–Paul Galmiche, Francis Bornet, Khaled Méflah	59

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact